Skip to content
Screener

Total Equity at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$967.52M+16.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.51B+55.4%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$614.86M+83.4%
Cytokinetics logo
CytokineticsCYTK
-$173.49M+52.9%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$1.03B-25.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$2.28B-38.2%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemJune 30, 2026December 31, 2025
Class B ordinary shares, nominal value of $0.000273235 per share; 895,158 shares and 1,795,158 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively11
Class A1 ordinary shares, nominal value of $0.000273235 per share; 12,781,964 shares issued and outstanding as of June 30, 2026 and December 31, 202544
Class B1 ordinary shares, $0.000273235 nominal value; 16,057,618 shares issued and outstanding as of June 30, 2026 and December 31, 202544
Additional paid-in capital1,069,6221,029,748
Accumulated other comprehensive loss(1,380)(25)
Accumulated deficit(414,114)(462,138)
Total shareholders’ equity654,149567,606
Total liabilities and shareholders’ equity$896,110$763,633

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's total equity?
Kiniksa Pharmaceuticals International, plc (KNSA) reported total equity of $654.15M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's total equity changed year-over-year?
Kiniksa Pharmaceuticals International, plc's total equity increased by 32.1% year-over-year, from $495.01M to $654.15M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total equity?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total equity has grown at a 12.7% compound annual growth rate (CAGR), from $311.94M to $567.61M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Kiniksa Pharmaceuticals International, plc's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude